Varenicline and neuronal nicotinic acetylcholine receptors: A new approach to the treatment of co-occurring alcohol and nicotine addiction?

American Journal on Addictions

Volumn 22, Issue 5, 2013, Pages 453-459

  Nocente, Roberto ^a   Vitali, Mario ^a,b   Balducci, Giuseppe ^a   Enea, Domenico ^a   Kranzler, Henry R ^c   Ceccanti, Mauro ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DOPAMINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3BETA4; NICOTINIC RECEPTOR ALPHA4BETA2; UNCLASSIFIED DRUG; VARENICLINE;

ABNORMAL DREAMING; AGITATION; ALCOHOL CONSUMPTION; ALCOHOL INTOXICATION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANTICIPATION; ARTICLE; BINGE DRINKING; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; COMPULSION; DECISION MAKING; DEPRESSION; DISEASE SEVERITY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DOSAGE SCHEDULE COMPARISON; DRUG RECEPTOR BINDING; DRUG SELF ADMINISTRATION; DYSPEPSIA; DYSPHORIA; FLATULENCE; HEADACHE; HOSTILITY; HUMAN; IMPULSIVENESS; INSOMNIA; LONG TERM EXPOSURE; MENTAL DISEASE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOOD; NAUSEA; NERVE CELL PLASTICITY; NEUROBIOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; PHENOMENOLOGY; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; SMOKING; SMOKING CESSATION; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM; VOMITING; WITHDRAWAL SYNDROME;

ALCOHOLISM; ANIMALS; BENZAZEPINES; HUMANS; NICOTINIC AGONISTS; QUINOXALINES; TOBACCO USE DISORDER;

EID: 84882575353     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2013.12037.x     Document Type: Article

References (75)

1. Nutt DJ, King LA, Phillips LD, et al. Drug harm in the UK: A multicriteria decision analysis. Lancet. 2010; 376: 1558-1565.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. Washington, D.C.: American Psychiatric Press; 2000.
3. Koob GF, Volkow ND., Neurocircuitry of addiction. Neuropsychopharmacology. 2010; 35: 217-238.
4. Kalivas PW, O'Brien C., Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology. 2008; 33: 166-180.
5. George O, Koob GF., Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2010. 35: 232-247.
6. Ceccanti M, Nocente R, Diurni V, et al. The nurse's role in the identification and the management of alcohol abuser in the emergency department (Ruolo dell'infermiere nell'identificazione e gestione del paziente con abuso alcolico nel dipartimento di emergenza). Clin Ter. 2002; 153: 389-396.
7. Ceccanti M, Sasso GF, Nocente R, et al. Hypertension in early alcohol withdrawal in chronic alcoholics. Alcohol Alcohol. 2006; 41: 5-10.
8. Goldstein RZ, Volkow ND., Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry. 2002; 159: 1642-1652.
9. Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug and addiction: Results from imaging studies and treatment implications. Mol Psychiatry. 2004; 9: 557-569.
10. Conte A, Attilia ML, Gilio F, et al. Acute and chronic effects of ethanol on cortical excitability. Clin Neurophysiol. 2008; 119: 667-674.
11. Zhou FC, Anthony B, Dunn KW, et al. Chronic alcohol drinking alters neuronal dendritic spines in the brain reward center nucleus accumbens. Brain Res. 2007; 1134: 148-161.
12. Lippman J, Dunaevsky A., Dendritic spine morphogenesis and plasticity. J Neurobiol. 2005; 64: 47-57.
13. Richards DA, Mateos JM, Hugel S, et al. Glutamate induces the rapid formation of spine head protrusions in hippocampal slice cultures. Proc Natl Acad Sci USA. 2005; 102: 6166-6171.
14. Baker DA, McFarland K, Lake RW, et al. Neuroadaptation in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci. 2003; 6: 743-749.
15. Jentsch JD, Taylor JR., Impulsivity resulting from frontostriatal dysfunction in drug abuse: Implications for the control of behavior by reward-related stimuli. Psychopharmacology. 1999; 146: 373-390.
16. Crunelle CL, Miller ML, Booij J, et al. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review. Eur Neuropsychopharmacol. 2010; 20: 69-79.
17. Koob GF, Kreek MJ., Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry. 2007; 164: 1149-1159.
18. Steensland P, Simms JA, Holgate J, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA. 2007; 104: 12518-12523.
19. Bierut LJ, Schuckit MA, Hesselbrock V, et al. Co-occurring risk factors for alcohol dependence and habitual smoking. Alcohol Res Health. 2000; 24: 233-241.
20. Madden PA, Heath AC., Shared genetic vulnerability in alcohol and cigarette use dependence. Alcohol Clin Exp Res. 2002; 26: 1919-1921.
21. Swan GE, Carmelli D, Cardon LR., Heavy consumption of cigarettes, alcohol and coffee in male twins. J Stud Alcohol. 1997; 58: 182-190.
22. Chatterjee S, Bartlett SE., Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS Neurol Disord Drug Targets. 2010; 9: 60-76.
23. Koob GF, Bloom FE., Cellular and molecular mechanism of drug dependence. Science. 1988; 242: 715-723.
24. Hendrickson LM, Rubing ZS, Xueyan P, et al. Activation of α4 NAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci. 2010; 30: 10169-10176.
25. Hendrickson LM, Gardner P, Tapper AR., Nicotinic acetylcholine receptors containing the α4 subunit are critical for nicotine-induced reduction of acute voluntary ethanol consumption. Channels (Austin). 2011; 5: 124-127 [Epub 2011 Mar 1].
26. Al-Rejaaie S, Dar SM., Antagonism of ethanol ataxia by intracerebellar nitric oxide and cGMP. Brain Res Bull. 2006; 69: 187-196.
27. Gould TJ, Lommock JA., Nicotine enhances contextual fear conditioning and ameliorates ethanol-induced deficits in contextual fear condition. Behav Neurosci. 2003; 117: 1276-1282.
28. Gould TJ, Collin AC, Wehner JM., Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition. Nicotine Tob Res. 2001; 3: 17-24.
29. Collins AC, Wilkins LH, Slobe BS, et al. Long-term ethanol and nicotine treatment elicit tolerance to ethanol. Alcohol Clin Exp Res. 1996; 20: 990-999.
30. Collins AC, Romm E, Selvaag S, et al. A comparison of the effects of chronic nicotine infusion on tolerance to nicotine and cross-tolerance to ethanol in long and short sleep mice. J Pharmacol Exp Ther. 1993; 266: 1390-1397.
31. Collins AC, Burch JB, de Fiebre CM, et al. Tolerance to a cross tolerance between ethanol and nicotine. Pharmacol Biochem Behav. 1988; 29: 365-373.
32. de Fiebre CM, Collins AC., A comparison of the development of tolerance to ethanol and cross tolerance to nicotine after chronic ethanol treatment in long and short sleep mice. J Pharmacol Exp Ther. 1993; 266: 1398-1406.
33. Burch JB, de Fiebre CM, Marks MJ, et al. Chronic ethanol or nicotine treatment results in partial cross-tolerance between these agent. Psychopharmacology. 1988; 95: 452-458.
34. de Fiebre CM, Marks MJ, Collins AC., Ethanol-nicotine interactions in long sleep and short sleep mice. Alcohol. 1990; 7: 249-257.
35. Williams KE, Reeves KR, Billing CB, et al. A double-blind study evaluating the long term safety of varenicline for smoking cessation. N Engl J Med. 1999; 340: 685-691.
36. Sargent PB., The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci. 1993; 16: 403-443.
37. Albuquerque EX, Pereira EF, Alkondon M, et al. Mammalian nicotinic acetylcholine receptors: From structure to function. Physiol Rev. 2009; 89: 73-120.
38. Chatterjee S, Bartlett SE., Neuronal nicotinic acetylcholine receptors as pharmaco-therapeutic targets for the treatment of alcohol use disorders. CNS Neurol Disorder Drug Targets. 2010; 9: 60-76.
39. Mihalak KB, Carroll FI, Luetje CW., Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006; 70: 801-805.
40. Hays JT, Ebbert JO., Varenicline for tobacco dependence. N Eng J Med. 2008; 359: 2018-2024.
41. Slater YE, Houlihan LM, Maskell PD, et al. Halogenated cytosine derivatives as agonists at human neuronal nicotinic acetylcholine receptors subtypes. Neuropharmacology. 2003; 44: 503-515.
42. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: An α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005; 48: 3474-3477.
43. Gonzales D, Rennard DI, Nides M, et al. Varenicline, an α4β2 nicotinic receptor partial agonist, vs. sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA. 2006; 296: 47-55.
44. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic receptor partial agonist, vs. placebo or sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA. 2006; 296: 1355.
45. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006; 166: 1561-1568.
46. Mills EJ, Wu P, Spurden D, et al. Efficacy of pharmacotherapies for short-term smoking abstinance: A systematic review and meta-analysis. Harm Reduct J. 2009; 6: 25.
47. Lancaster T, Stead L, Cahill K., An update on therapeutics for tobacco dependence. Expert Opin Pharmacother. 2008; 9: 15-22.
48. Ebbert JO, Hays JT, Hurt RD., Combination pharmacotherapy for stopping smoking: What advantages does it offer ? Drugs. 2010; 70: 643-650.
49. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA. 2006; 296: 64-71.
50. Ericson M, Löf E, Stomberg R, et al. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther. 2009; 329: 225-230.
51. McKee SA, Harrison ELR, O'Malley SS, et al. Varenicline reduces alcohol self administration in heavy-drinking smokers. Biol Psychiatry. 2009; 66: 185-190.
52. U.S. Preventive Service Task Force. Agency for Healthcare Research and Quality (2003) Counselling to prevent tobacco use and tobacco-caused disease: Recommendation statement. Available at: http://www.ahrq.gov/clinic/3rduspstf/ tobacconun/tobcounrs.pdf. Accessed October 10, 2008.
53. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline a selective, α4β2 nicotinic receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006; 34: 121-130.
54. Patterson F, Jepson C, Loughead J, et al. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend. 2010; 106: 61-64.
55. Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry. 2009; 65: 144-149.
56. CHANTIX, U.S., (Revised 4/2010). Physician Prescribing Information. Available at www.pfizer.com.
57. Pirmoradi P, Roshan S, Nadeem SS., Neuropsychiatric disturbance after initiation of varenicline in a patient with history of alcohol abuse and major depression. Am J Health Syst Pharm. 2008; 65: 1624-1626.
58. Mahendri RB, Kutscher EC., Visual hallucinations associated with varenicline: A case report. J Med Case Rep. 2009; 3: 7560.
59. Freedman R., Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007; 164: 1269.
60. Kohen I, Kemen N., Varenicline-induced maniac episode in a patient with bipolar disorder. Am J Psychiatry. 2007; 164: 1270.
61. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. CMAJ. 2011; 183: 1359-1366.
62. Bito-Onon JJ, Simms JA, Chatterjee S, et al. Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats. Addict Biol. 2006; 16: 440-449.
63. Wouda JA, Riga D, De Vries W, et al. Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl). 2011; 216: 267-277.
64. Kamens HM, Andersen J, Picciotto MR., The nicotinic acetylcholine receptor partial agonist varenicline increases the ataxic and sedative-hypnotic effects of acute ethanol administration in C57BL/6J mice. Alcohol Clin Exp Res. 2010; 34: 2053-2060.
65. Kamens HM, Andersen J, Picciotto MR., Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl). 2010; 208: 613-626.
66. Gulick D, Gould TJ., Varenicline ameliorates ethanol-induced deficit in learning in C57 BL/6 mice. Neurobiol Learn Mem. 2008; 90: 230-236.
67. Chatterjee S, Steensland P, Simms JA, et al. Partial agonist of the α3β4 neuronal nicotinic acetylcholine receptor reduces ethanol consumption and seeking in rats. Neuropsychopharmacology. 2011; 36: 603-615.
68. Fucito LM, Toll BA, Wu R, et al. A preliminary investigation on varenicline for heavy drinking smokers. Psychopharmacology. 2011; 215: 655-663.
69. Johnson BA., Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol. 2008; 75: 34-56.
70. Herz A., Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997; 129: 99-111.
71. De Witte P, Littleton J, Parot P, et al. Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs. 2005; 19: 517-537.
72. Mann K, Kiefer F, Smolka M, et al. Searching for responder to acamprosate and naltrexone in alcoholism treatment: Rationale and design of the predict study. Alcohol Clin Exp Res. 2009; 33: 1-10.
73. Sofuoglu M., Cognitive enhancement as pharmacotherapy target for stimulant addiction. Addiction. 2010; 105: 38-48.
74. Loughead J, Ray R, Wileyto EP, et al. Effects of the α4β2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry. 2010; 67: 715-721.
75. Blomqvist O, Ericson M, Johnson DH, et al. Voluntary ethanol intake in the rat: Effects of nicotinic acetylcholine receptor blockade or subchronic. Eur J Pharmacol. 1996; 314: 257-267.